Neurocrine Biosciences, Inc. (NASDAQ:NBIX) CEO Kyle Gano Sells 980 Shares

Neurocrine Biosciences, Inc. (NASDAQ:NBIX) CEO Kyle Gano sold 980 shares of the stock in a transaction on Monday, February 10th. The stock was sold at an average price of $118.39, for a total transaction of $116,022.20. Following the sale, the chief executive officer now owns 137,658 shares of the company’s stock, valued at approximately $16,297,330.62. This represents a 0.71 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link.

Kyle Gano also recently made the following trade(s):

• On Friday, January 31st, Kyle Gano sold 1,541 shares of Neurocrine Biosciences stock. The stock was sold at an average price of $152.87, for a total transaction of $235,572.67.
• On Wednesday, January 15th, Kyle Gano sold 65,000 shares of Neurocrine Biosciences stock. The shares were sold at an average price of $141.50, for a total value of $9,197,500.00.

Neurocrine Biosciences Trading Down 1.6 %

NASDAQ:NBIX opened at $115.02 on Friday. The company has a market capitalization of $11.65 billion, a P/E ratio of 34.96 and a beta of 0.33. The firm has a 50-day moving average price of $138.09 and a two-hundred day moving average price of $130.82. Neurocrine Biosciences, Inc. has a twelve month low of $110.95 and a twelve month high of $157.98.

Neurocrine Biosciences (NASDAQ:NBIX) last issued its quarterly earnings data on Thursday, February 6th. The company reported $1.00 earnings per share for the quarter, missing analysts’ consensus estimates of $1.62 by ($0.62). Neurocrine Biosciences had a return on equity of 13.45% and a net margin of 14.49%. On average, equities research analysts predict that Neurocrine Biosciences, Inc. will post 6.53 earnings per share for the current year.

Hedge Funds Weigh In On Neurocrine Biosciences

A number of institutional investors have recently made changes to their positions in NBIX. Dodge & Cox increased its position in Neurocrine Biosciences by 134.2% during the 4th quarter. Dodge & Cox now owns 3,016,425 shares of the company’s stock worth $411,742,000 after purchasing an additional 1,728,605 shares in the last quarter. Raymond James Financial Inc. acquired a new stake in shares of Neurocrine Biosciences during the 4th quarter worth about $115,193,000. Wellington Management Group LLP boosted its stake in shares of Neurocrine Biosciences by 102.9% during the 4th quarter. Wellington Management Group LLP now owns 1,457,425 shares of the company’s stock worth $198,939,000 after purchasing an additional 739,199 shares during the last quarter. Thrivent Financial for Lutherans grew its holdings in shares of Neurocrine Biosciences by 2,759.4% during the fourth quarter. Thrivent Financial for Lutherans now owns 737,772 shares of the company’s stock worth $100,705,000 after buying an additional 711,970 shares in the last quarter. Finally, State Street Corp lifted its stake in shares of Neurocrine Biosciences by 11.7% during the third quarter. State Street Corp now owns 5,148,293 shares of the company’s stock valued at $593,186,000 after buying an additional 539,936 shares during the period. 92.59% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

Several research analysts have weighed in on the company. Royal Bank of Canada lowered their target price on Neurocrine Biosciences from $154.00 to $148.00 and set a “sector perform” rating on the stock in a research note on Friday, February 7th. Barclays lifted their price objective on shares of Neurocrine Biosciences from $160.00 to $165.00 and gave the company an “overweight” rating in a research report on Monday, December 23rd. Wedbush cut their price objective on shares of Neurocrine Biosciences from $157.00 to $147.00 and set an “outperform” rating for the company in a research report on Friday, February 7th. Canaccord Genuity Group lowered their target price on shares of Neurocrine Biosciences from $172.00 to $163.00 and set a “buy” rating on the stock in a report on Friday, February 7th. Finally, Piper Sandler reissued an “overweight” rating and set a $160.00 price target on shares of Neurocrine Biosciences in a report on Monday, December 23rd. Five investment analysts have rated the stock with a hold rating, seventeen have issued a buy rating and two have issued a strong buy rating to the stock. According to data from MarketBeat, Neurocrine Biosciences presently has a consensus rating of “Moderate Buy” and a consensus target price of $166.90.

Neurocrine Biosciences Company Profile

Neurocrine Biosciences, Inc discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company’s products include INGREZZA for tardive dyskinesia and chorea associated with Huntington’s disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.